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Oral Presentations 1746 years (range 1–71)] between 10/05-5/08 with the hypothesis that
CB would extend transplant access. Adequate donor-recipient HLA-
match was $8/10 HLA-A,B,C,DRB1,DQ alleles for a T cell de-
pleted or $9/10 alleles for an unmodified URD graft. Adequate
CB units were $4/6 HLA-A,B antigen, DRB1 allele matched &
$1.5 107 TNC/kg/unit. Double unit grafts were used to augment
engraftment. URDs had priority; CB was chosen if no suitable URD
was available in the required time period. The 309 patients had
highly diverse ancestry with only 68 (22%) of northwest (NW) Eu-
ropean & 108 (35%) of non-European origin. The ancestry of 201
transplanted patients & the 15 not transplanted due to lack of suit-
able graft is shown below. The remaining 93 patients were not trans-
planted for other reasons. URD transplant recipients were
predominantly NW (32%), eastern (18%) or mixed (18%) European
with Asian, African & Hispanic patients combined accounting for
only 18%. In contrast, only 4 (8%) of CBT recipients were NW
European. While these patients received CB due to urgency (n 5
1), patient preference (n 5 1), or MD preference over mismatched
URD (n 5 2), the remaining 48 (92%) of CBT recipients including
15% Southern Europeans and 49% non-Europeans (13% Asian,
19% African, 15% Hispanic, 2% Middle Eastern) had no URD op-
tion. Of 15 patients not transplanted due to lack of any HSC source
10 were non-European including 6 of African ancestry. Their me-
dian weight [87kg (range 66–151)] was significantly higher than
CBT recipients [70kg (range 13–109); p\0.01] partially accounting
for their lack of suitable CB grafts. Thus, URD transplantation pre-
dominantly serves patients of NW, Eastern & mixed European an-
cestry with many Southern & non-Europeans having no suitable
URD. In contrast, CB significantly extends transplant access to all
but especially to both Southern & non-Europeans. Patients of
African ancestry are the most challenged to secure a suitable graft.
This data is compelling support for increased funding of public
CB banking & suggests that CB has the greatest potential to fulfill
the promise of being able to offer allograft to all regardless of race.
Patient Ancestry if Transplanted or No Graft
8-10/10 URD (n5149) 4-6/6 CB (n552) No graft (n515)NW Europe 47 (32%) 4 (8%) 1 (7%)
East Europe 27 (18%) 6 (12%) 0 (0%)
South Europe 15 (10%) 8 (15%) 3 (20%)
Mix: Europe 27 (18%) 8 (15%) 1 (7%)
Asian 6 (4%) 7 (13%) 0 (0%)
African 11 (7%) 10 (19%) 6 (40%)
Hispanic 10 (7%) 8 (15%) 3 (20%)
Middle East 5 (3%) 1 (2%) 0 (0%)
Mix: Non-Europe 1 (1%) 0 (0%) 1 (7%)*Significantly different (p#0.05).39
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Washing of CB after thawing prior to infusion into patients (pts)
is an accepted practice in CB transplantation. The potential clinical
benefits were extrapolated from early in vitro studies using units
processed by RBC reduction (RCR) with hetastarch. Other proce-
dures for processing (PD, RCR using gelatin or buffy coat) have
produced equally high quality CB with similar clinical outcome.
In this report, we analyzed the impact of post-thaw washing (W)
on clinical outcome using PD CB. A total of 487 PD CB was in-
fused into 434 pts with malignant or non-malignant diseases.
The decision to wash (222 pts) or not to wash (NW) CB after
thawing was at the discretion of individual transplant centers. Pt
matching was used to compare the W and NW cohorts. Pts wereassigned propensity scores based on age, weight, number of infused
CB, total nucleated cell (NC) dose, and HLA mismatches, then
each pt in the NW group was assigned a pt in the W group with
the nearest score to form a pair, allowing us to form a group of
129 W pts with the same diagnoses as those in a group of 129
NW pts. Outcome parameters including cumulative incidence
(CI) and days to ANC 500 and platelet 20k engraftment, grade
III-IV acute graft-versus-host-disease (aGvHD), extensive chronic
graft-versus-host-disease (cGVHD), 100-day and 1-year transplant
related mortality (TRM), 1-year relapse rate, OS and DFS, were
summarized in the table below. The analyses confirm that pts re-
ceiving NW CB have similar (aGvHD, relapse) or superior clinical
outcomes (ANC and platelet engraftment, cGVHD, TRM, OS and
DFS) to those receiving W units. It should be pointed out that
although the 100-day TRM appeared similar, the 1-year TRM
diverged significantly for the 2 groups. Pts receiving NW CB
had higher incidences of limited cGvHD but lower incidences of
extensive cGvHD as compared to those receiving W CB. Despite
this reduction in the severity and lower cumulative incidence of ex-
tensive cGvHD, pts receiving NW and W PD CB have similar re-
lapse rates, suggesting that Graft-versus-Leukemia effects may not
be compromised in the NW group. These observations also sug-
gest there may be a potential immunomodulatory mechanism
whereby the severity of cGvHD is reduced, which may contribute
to improved survival. In conclusion, our results suggest that post-
thaw washing of PD CB may be associated with poorer clinical out-
comes and prospective investigation on the effect of washing on
post CB transplant management may be warranted.
Impact of post-thaw washing of PD CB — All patients
Gr TRM*ANC
500* (d)Plt
20k* (d)III-IV
aGvHDExtensive
cGvHD*100
d/1 yr Relapse OS*/DFS*Washed 8564%
(27)6364%
(55)1563% 1663% 1863%/3464% 3165% 5464%/
4664%Unwashed 8665%
(20.5)7765%
(45)1763% 462% 1663%/2263% 2365% 6963%/
6264%Impact of post-thaw washing of PD CB — Matched PairsANC
500*
(d)Plt 20k*
(d)Gr III-IV
aGvHDExtensive
cGvHD*TRM* 100
d/1 yrRelapse OS*/
DFS*Washed 8366%
(28)5866%
(56.5)1463% 1764% 2164%/4165% 2866% 4865%/
4365%Unwashed 8966%
(21)7867%
(45)1464% 462% 1463%/2164% 2466% 6964%/
6165%40
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The naive phenotype of cord blood (CB) cells contributes to the
lower incidence and reduced severity of GvHD after umbilical cord
blood transplant (CBT). However, the relatively low cell numbers
and naivety of T-cell populations in CB grafts has lead to delayed im-
mune reconstitution and higher mortality due to infection. CMV and
adenovirus (Adv) are particularly problematic infections in patients af-
ter CBT. Previous studies have shown that adoptive immunotherapy
with peripheral blood-derived CTL directed against CMV and Adv
can effectively prevent the clinical manifestations of these viruses after
HSCT suggesting that a similar approach could be developed after
CBT. We hypothesized that CTL could be generated from CB for
clinical use to restore anti-viral immunity and reduce viral infection
post CBT. 40 106 CB mononuclear cells (available in the 20% frac-
tion of frozen CB units) were thawed and used for generation of bi-vi-
rus specific CTL. A clinical-grade recombinant Adv type 5 vector
pseudotyped with a type35 fiber carrying a transgene for CMVpp65
18 Oral Presentationsas a source of Adv and CMV antigens. CB-derived dendritic cells were
transduced with the Ad5f35pp65 vector to stimulate virus-specific
CTL followed by stimulation with autologous CB-derived lympho-
blastoid cells (LCL) transduced with the same vector. After 3 weeks ex-
pansion, 9 CTL lines contained a mean of 83% (range 64–94%)
CD81 and 27% (range 12–40%) CD41 T-cells. Flow cytometric
analysis of memory markers revealed a predominance of CD45RA-
CD62L- T-cells (69618%; range 25–93) with a smaller population
of CD45RA- CD62L1 T-cells (1065%; range 1–23). Evaluable
CB CTL lines showed specific cytolytic activity in 51Cr release assays
against CMV and Adv targets. IFNg ELISPOT assays on CTL lines
demonstrated a mean of 209 (range 45–694) and 74 (range 0–188)
spot-forming cells/1  105 T-cells following incubation with CMV-
pp65 and Adv-hexon/penton peptides respectively. No significant re-
sponse to irrelevant peptides was demonstrated. The expanded CB
CTL had a broad Vb repertoire and were specific for multiple viral
epitopes. In addition, the virus-specific T cells were shown to be ex-
panded only from T-cells with a naive phenotype (CD45RA1/
CCR71). These results demonstrate that, despite the generally naive
nature of CB lymphocytes, bi-virus-specific responses can be ex-
panded in vitro and could potentially be used clinically in CBT patients
who develop infectious complications prior to immune reconstitution.41
THE ‘‘MARROWMINER’’, A NOVEL, MINIMALLY INVASIVE DEVICE FOR
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Introduction: Bone marrow (BM) is the traditional graft source in
hematopoietic stem cell transplantation. An increasing body of work
suggests thatuseofBMgraftsmayshow long-term advantages over mo-
bilized PBSC in some alloegeneic settings, resulting in less cGVHD,
morbidity and improved survival. Traditional O.R. based BM harvest
methods are crude, labor and resource intensive, generally requiring
100–2001 serial small volume needle aspirates, and result in grafts
highly diluted by peripheral blood. Improved BM harvest methods
are needed. The ‘‘MarrowMiner’’ (MM), is a novel, FDA cleared and
CE-Marked device developed for the minimally invasive harvest of
BM to enable the rapid, convenient, outpatient harvest of large quanti-
ties of BM via a single marrow entry site, under local anesthesia.
Methods:The MARVELOUS (MARrowMinerVErsus standard
ILeac bOne marrow pUncture and aSpiration) trial was designed to
compare harvest of the MM with standard serial-puncture needle
harvest in the same patient. 21 patients undergoing autologous mar-
row derived cell therapy were enrolled, and had BM harvested under
local anesthesia from their anterior (10) or posterior (11) ileac by the
MM, followed by serial marrow aspirates with standard 6-hole
harvest needles from the opposite hip. Cell viability, counts,
CD341, ALDH1, T cell, and MSC populations were compared.
Results: The MM successfully harvested large volumes (up to
300ml) of marrow under local anesthesia without any complications.Average intrapatient ratio of cell counts from marrow ob-
tained by MarrowMiner and by standard harvest aspirate
method
Total
Nucleated
Cell Count /
ml % CD341 % CD31
% MSC
phenotype
%
ALDH1
Mean ratio:
Marrow
Miner counts /
Standard
Harvest
counts
1.98 1.22 0.78 7.96 3.56
*Results from initial 10 of 21 patients with full flow cytometry data avail-
able at time of submission.MM harvest samples had a greater average TNC count / ml
compared to standard marrow harvest in the same patient (1.98
greater TNC (0.87–3.3 6 p\.05). Viability was equivalent at
(.99%). In addition to higher TNC/ml, higher levels (mean 3.56
fold) of % ALDH1, CD341, phenotypic MSC (7 fold) and CFU
were obtained by MM while % CD31 was lower.
Conclusions: The novel MarrowMiner system demonstrated
safety and efficacy in clinical use, while harvesting more CD341
cells per ml via single iliac entry compared to standard harvest
methods. This suggests the MM may enable improved clinical har-
vests in a more rapid and minimally invasive manner, improving
donor safety and convenience while obtaining a richer marrow prod-
uct, requiring less total volume and with less peripheral blood con-
tamination. Such a system, facilitating convenient, on demand
stem cell collection and improved safety and convenience for the do-
nor may have significant application for BMT and other marrow
based cell therapies.42
IN UTERO GENE AND CELL THERAPY FOR CONGENITAL DISEAASES
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In utero stem cells transplantation (IUSCT) presents immunolog-
ical and therapeutic potentials advantages over postnatal stem cells
transplantation (SCT).The peculiar, immunological status of the fe-
tus allows donor-specific tolerance and can eliminate the require-
ment of pharmacological immunosuppression. Furthermore
IUSCT potentially prevents clinical manifestations that can start at
this stage of development and, indeed, the small size of the foetus al-
lows a much higher relative doses of stem cells, favouring successful
engraftment. Mesenchymal stem cells (MSCs) are multipotent stem
cells able to differentiate into diverse lineages, including osteocytes,
chondrocytes, adipocytes. MSCs have a peculiar homing-capacity,
when injected in animal models, colonizing irradiated mesoderm-
derived tissues, ischemic myocardium, liver and brain.On the ratio-
nal of their trafficking capacity to injured tissues, clinical trials have
been started with the employment of MSCs in the treatment of met-
abolic diseases like Hurler syndrome and metachromatic leukodys-
trophy, or Osteogenesis Imperfecta (OI). Our centre performed
seven in utero transplants in foetuses affected by SCID and Osteo-
genesis Imperfecta with improvement of clinical presentation in
most cases and low procedure related morbility. SCID fetuses have
been transplanted with haematopoietic CD341 stem cells, in three
cases MSC were coinjected (2 OI;1 SCID). With the aim of realizing
a prenatal gene therapy protocol, our group has successfully isolated,
expanded and characterized human multi-potent MSCs from 11
samples of second-trimester amniotic fluid. These cells result to be
expandable in specific conditions and to express mesenchymal
markers, above all between te 3rd and the 4th week of colture.Telo-
merase activity and telomers length have been evaluated demonstrat-
ing an absent spontaneous transformation tendency. Transduction
efficacy of Amniotic Fluid Mesenchymal Stem Cells (AFMSC) has
been assessed using a SIN HIV-1–based lentiviral vector. This vec-
tor encloses SFFV-U3 promoter and eGFP.We found a transduction
efficiency of 60%. We suggest that AFMSCs, with their ready
expandability, ability to differentiate into multiple lineages and
high transduction efficiency, may be good target for neonatal regen-
erative surgery and for in utero gene therapy for diseases candidate
(i.e.x-SCID, CGD, WAS,ADA- SCID).43
THE EFFECT OF INHIBITORY KILLER-CELL IG-LIKE RECEPTOR(IKIR)
MATCHING IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION(HCT)
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Successful treatment of hematological malignancy by HCT is
complicated by the intensity of alloimmune response; too
strong—GVHD, or too weak—relapse. Natural Killer (NK) cell
